Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Active, not recruiting · NCT04626024 · Registry updated 2026-05-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-05-04 | NCT04626024 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Baylor College of Medicine | 267 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine- McNair Campus | Houston | United States | 2 |
| Ben Taub General Hospital | Houston | United States | 65 |
| CHI St. Luke's Health Baylor College of Medicine Medical Center | Houston | United States | 6 |
| Harris Health System- Smith Clinic | Houston | United States | 1 |